Our Editor-in-Chief, Axel Merseberger (University Hospital Schleswig-Holstein), joined us at ESMO 2019 to discuss current limitations in the treatment of metastatic hormone-sensitive prostate cancer, use of antiandrogen agents, and what the future may hold.
Questions
1. What are the limitations of the current standard of care for metastatic hormone-sensitive prostate cancer (mHSPC)? (0:05)
2. What have recent clinical studies taught us about the optimum use of the antiandrogen agents enzalutamide, abiraterone acetate and apalutamide in the treatment of men with mHSPC? (0:40)
3. What factors should be considered when making treatment decisions for mHSPC? (1:22)
4. What is the safety profile of the anti-androgen agents? (2:02)
5. What future role do you see for chemotherapy in the treatment of mHSPC? (2:52)
6. What do you expect to be the next major breakthrough in the treatment of mHSPC? (3:49)
Filmed at the European Society for Medical Oncology (ESMO) Congress 2019, Barcelona, Spain.
Speaker disclosure: Axel Merseberger has nothing to disclose in relation to this video.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
